EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paraskeletal disease in multiple myeloma after treatment: is there a possible prognostic role of whole-body low dose CT (WBLDCT) vs. 18 F-FDG-PET/CT?

Davide Bezzi, Elena Zamagni, Martina Di Franco, Marco Talarico, Vincenza Solli, Katia Mancuso, Simona Barbato, Arrigo Cattabriga, Stefano Brocchi, Cristina Mosconi, Cristina Nanni

Clinical and Translational Imaging · 19.07.2026

DOI: 10.1007/s40336-026-00788-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Imaging, online erschienen am 19.07.2026. Verfasst von Davide Bezzi und 10 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post-therapy assessment of paraskeletal plasmacytoma (PM) in multiple myeloma (MM) relies on lesion persistence and/or size changes on whole-body low-dose CT (WBLDCT).

Purpose

To evaluate the prognostic value of WBLDCT and 18 F-FDG-PET/CT (PET/CT) before and after therapy in newly diagnosed MM patients with PM, and a small subgroup with solitary plasmacytoma (PSO), aiming to refine future imaging response criteria.

Methods

We retrospectively reviewed PET/CT and WBLDCT images of 42 patients (39 MM, 3 PSO) undergoing first-line therapy from October 27, 2016, to June 12, 2021. Imaging including criteria were a positive PET/CT scan at baseline and a subsequent negative PET/CT scan prior to starting maintenance. Negative PET/CT was defined applying Deauville criteria for focal, PM, and bone marrow uptake, with complete metabolic response defined as uptake below liver background (Deauville scores < 4). PET parameters (IMPeTUs criteria), CT morphological/technical features, and baseline laboratory data were assessed using univariate and multivariate analyses for their impact on clinical outcomes.

Results

Pre-maintenance SUVmax of the PM lesions predicted adverse progression-free survival (PFS) and Deauville Score 3 identified patients with significantly worse PFS (median 27 months vs. not reached; HR = 3.45, p = 0.05) and showed a trend toward inferior overall survival (OS) (52 months vs. not reached; HR = 2.99, p = 0.16), remaining an independent prognostic factor. In transplanted patients ( n = 32), PM Deauville Score 3 predicted inferior PFS (median 27 vs. 74 months, p = 0.015) and OS (39 months vs. not reached, p = 0.03). CT had limited prognostic value, except for pre-maintenance transverse diameter (PFS: HR = 1.86, p = 0.02) and absence of cortical bone regeneration.

Conclusions

Pre-maintenance PM Deauville Score 3 has been shown to be representative of adverse outcomes, highlighting the added prognostic value of 18F-FDG-PET/CT over WBLDCT alone, and the possibility of refining future PET monitoring in this patient population.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Bezzi, D., Zamagni, E., Franco, M. D., Talarico, M., Solli, V., Mancuso, K., Barbato, S., Cattabriga, A., Brocchi, S., Mosconi, C., & Nanni, C. (2026). Paraskeletal disease in multiple myeloma after treatment: is there a possible prognostic role of whole-body low dose CT (WBLDCT) vs. 18 F-FDG-PET/CT?. Clinical and Translational Imaging. https://doi.org/10.1007/s40336-026-00788-2

Vancouver

Bezzi D, Zamagni E, Franco MD, Talarico M, Solli V, Mancuso K, et al. Paraskeletal disease in multiple myeloma after treatment: is there a possible prognostic role of whole-body low dose CT (WBLDCT) vs. 18 F-FDG-PET/CT?. Clinical and Translational Imaging. 2026. doi:10.1007/s40336-026-00788-2

BibTeX
@article{Bezzi2026,
  author = {Bezzi, Davide and Zamagni, Elena and Franco, Martina Di and Talarico, Marco and Solli, Vincenza and Mancuso, Katia and Barbato, Simona and Cattabriga, Arrigo and Brocchi, Stefano and Mosconi, Cristina and Nanni, Cristina},
  title = {Paraskeletal disease in multiple myeloma after treatment: is there a possible prognostic role of whole-body low dose CT (WBLDCT) vs. 18 F-FDG-PET/CT?},
  journal = {Clinical and Translational Imaging},
  year = {2026},
  doi = {10.1007/s40336-026-00788-2}
}
Kostenlos starten →